Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 4/20 | 0.40 |
| ▸ | ADH1A | P07327 | 4/20 | 0.40 |
| ▸ | ADH1C | P00326 | 3/20 | 0.40 |
| ▸ | ADH7 | P40394 | 3/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | ADH4 | P08319 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22794222 | 0.98 | ADH1B (0.39) | ADH1BADH1AADH1CADH7EPHX1 | |
| SCHEMBL24607335 | 0.92 | ADH1B (0.43) | ADH1BADH1AADH1CADH7EPHX1 | |
| SCHEMBL25827892 | 0.89 | ADH1B (0.43) | ADH1BADH1AADH1CADH7EPHX1 | |
| SCHEMBL23377979 | 0.88 | ADH1B (0.43) | ADH1BADH1AADH1CADH7EPHX1 | |
| SCHEMBL27129906 | 0.81 | TDP1 (0.31) | MEN1KMT2A | |
| SCHEMBL18908679 | 0.80 | ADH1B (0.43) | ADH1BADH1AADH1CADH7EPHX1 | |
| SCHEMBL23378342 | 0.79 | ADH1B (0.46) | ADH1BADH1AADH1CADH7EPHX1 | |
| SCHEMBL271073 | 0.79 | — | — | |
| SCHEMBL8186479 | 0.79 | ADH1B (0.54) | ADH1BADH1AADH1CADH7EPHX1 | |
| SCHEMBL10940490 | 0.78 | ADH1B (0.48) | ADH1BADH1AADH1CADH7EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022125790-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |